About Cenobamate

Arvelle Therapeutics is responsible for the development and commercialisation of cenobamate, an investigational anti-seizure medication, in the European market.

About Cenobamate

International Epilepsy Day

Join Arvelle and help promote the “50 Million Steps for Epilepsy” campaign

Find out more

Media

Press Releases and Events

View all

Angelini Pharma finalizes the acquisition agreement

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments

Arvelle Announces Partnership with Durbin Across Europe